hydroxymethyl carbamic acid benzyl ester | 31037-42-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: hydroxymethyl carbamic acid benzyl ester
• 英文别名: benzyl N-(hydroxymethylene)carbamate；benzyl N-(hydroxymethyl)-carbamate；benzyl N-(hydroxymethyl)carbamate；N-hydroxymethyl benzylcarbamate；benzyl hydroxymethylcarbamate；phenylmethyl (hydroxymethyl)Carbamic acid；Carbamic acid, (hydroxymethyl)-, phenylmethyl ester
• CAS: 31037-42-0
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: RWFPWQCNFWWIAE-UHFFFAOYSA-N

物化性质

• 熔点：
  84-85.5 °C
• 沸点：
  348.3±35.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  hydroxymethyl carbamic acid benzyl ester 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 dimethyl N-(benzyloxycarbonyl)aminomethylphosphonate
  参考文献：
  名称：

  相邻基团对疏水结合热力学的影响：疏水效应增加了复杂的方面

  摘要：

  使用等温滴定量热法（ITC）对在浅疏水口袋中结合的配体侧链进行系统修饰的热力学后果进行了评估，无论是否存在相邻的配体羧酸酯基团。数据显示，羧酸盐可能会通过改变未结合状态和结合状态下水合水的H键/组织状态来显着改变这些修饰的相对热力学特征。发现该羧酸酯基团在某些情况下是前焓的，对熵的，而在另一些情况下是反焓的，对熵的。还观察到了显着的焓-熵补偿关系，这反映了疏水作用受相关水环境的热力学状态支配的事实。

  DOI：

  10.1021/jm401609a
• 作为产物：
  描述：

  聚合甲醛 、 单体N-苄基氨基甲酸 在 potassium carbonate 作用下， 以 水 为溶剂， 反应 0.5h， 以44%的产率得到hydroxymethyl carbamic acid benzyl ester
  参考文献：
  名称：

  A Useful Modification of theEvans Auxiliary: 4-Isopropyl-5,5-diphenyloxazolidin-2-one

  摘要：

  The 4-isopropyl-5,5-diphenyloxazolidinone (1) is readily prepared from (R)- or (S)-valine ester, PhMgBr, and ethyl chlorocarbonate. It has a melting point of ca. 250 degrees, a low solubility in most organic solvents, and a C=O group which is sterically protected from nucleophilic attack. Thus; the soluble N-acyl-oxazolidinones (7-16) can be prepared from 1 with BuLi at temperatures around 0 degrees instead of - 78 degrees (Scheme 3): their Li enolates can be generated with BuLi, rather than with LDA, and deacylation in the final step of the procedure can be achieved with NaOH at ambient temperatures (Scheme 12),with facile recovery of the precipitating auxiliary 1 (filtering, washing, and drying). The following reactions of N-acyl-oxazolidinones from 1 have been investigated: alkylations (Scheme 4), aminomethylations and hydroxymethylations (Scheme 5), aldol additions (Schemes 6 and 7), Michael additions (Schemes 9 and 10), and a (4 + 2) cycloaddition (Scheme II). The well-known features of reactions following the Evans methodology (yield, diastereoselectivity, dependence on conditions, counter ions, additives etc.) prevail in these transformations. Most products, however, have higher melting points and a much more pronounced crystallization tendency than those derived from conventional oxazolidinones, and can thus be purified by recrystallization, avoiding chromatography (Table 1). The disadvantage of 1 having a higher molecular weight (ca. 150 Da) than the non-phenyl-substituted auxiliary is more than compensated by the ease of its application, especially on large scale. A number of crystal structures of oxazolidinones derived from 1 and a TICl4 complex of an oxazolidinone are described and discussed in view of the diastereoselective-reaction mechanisms.

  DOI：

  10.1002/(sici)1522-2675(19981111)81:11<2093::aid-hlca2093>3.0.co;2-x

文献信息

• [EN] C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE TÉTRACYCLINE C7-FLUOROSUBSTITUÉE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010017470A1

  公开（公告）日：2010-02-11

  The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

  本发明涉及一种由结构式（A）表示的化合物，或其药学上可接受的盐。结构式（A）的变量在此处定义。还描述了包括结构式（A）化合物的药物组合物及其治疗用途。
• Tetracycline compounds
  申请人：Chen Chi-Li

  公开号：US09315451B2

  公开（公告）日：2016-04-19

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式（I）表示的化合物，或其药学上可接受的盐。结构式I的变量在此处定义。还描述了包括结构式I化合物的药物组合物及其治疗用途。
• An Allyl Protection and Improved Purification Strategy Enables the Synthesis of Functionalized Phosphonamidate Peptides
  作者：Gerhard Klebe、Jonathan Cramer

  DOI：10.1055/s-0036-1588393

  日期：——

  biophysical methods such as isothermal titration calorimetry, high purity of the inhibitor of interest is indispensable. Herein, we describe a procedure for the synthesis and purification of functionalized phosphonamidate peptides that is able to generate inhibitors for the metalloprotease thermolysin for use in biophysical experiments. The method utilizes an allyl ester/alloc protection strategy and

  摘要 对于现代生物物理方法，例如等温滴定热法，目标抑制剂的高纯度是必不可少的。在本文中，我们描述了一种合成和纯化功能化膦酰胺酸肽的程序，该程序能够生成金属蛋白酶嗜热菌蛋白酶的抑制剂，用于生物物理实验。该方法利用了烯丙基酯/分配保护策略，并利用了快速有效的固相萃取（SPE）纯化步骤。应用该策略，我们能够合成一系列具有极高纯度的氨基和羟基官能化侧链的高极性抑制剂。 对于现代生物物理方法，例如等温滴定热法，目标抑制剂的高纯度是必不可少的。在本文中，我们描述了一种合成和纯化功能化膦酰胺酸肽的程序，该程序能够生成金属蛋白酶嗜热菌蛋白酶的抑制剂，用于生物物理实验。该方法利用了烯丙基酯/分配保护策略，并利用了快速有效的固相萃取（SPE）纯化步骤。应用该策略，我们能够合成一系列具有极高纯度的氨基和羟基官能化侧链的高极性抑制剂。
• [EN] TRIPHENYLPHOSPHONIUM-TETHERED TETRACYCYCLINES FOR USE IN TREATING CANCER<br/>[FR] TÉTRACYCLINES ATTACHÉES AU TRIPHÉNYLPHOSPHONIUM DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DU CANCER
  申请人：NOVINTUM BIOTECHNOLOGY GMBH

  公开号：WO2018193114A1

  公开（公告）日：2018-10-25

  This invention relates to compounds of formula (I) that are useful as cancer therapies. The compounds comprise derivatives of tetracycline antibiotics, e.g. doxycycline, having a phosphonium cation tethered to the tetracycline tetracycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.

  这项发明涉及作为癌症治疗药物有用的化合物(I)。这些化合物包括四环素抗生素的衍生物，例如强力霉素，其磷酸铵阳离子与四环素四环相连。该发明还涉及使用所述化合物的方法以及包含所述化合物的药物配方。
• Convergent asymmetric route to produce a key intermediate towards the synthesis of a garft inhibitor
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：US20040266827A1

  公开（公告）日：2004-12-30

  The invention relates to processes for the preparation of a key intermediate in the synthesis of a GARFT inhibitor of formula (Ia) containing a 4-methyl-substituted thiophene core: 1 wherein said key intermediate has the following formula (I): 2 wherein each of R 1 and R 2 are independently a moiety that together with the attached CO 2 forms a readily hydrolyzable ester group; from a compound of the formula (VI): 3 wherein R 1 is as described above, Pg 1 is an amino protecting group, and Pg 2 is an ether protecting group; wherein said processes are as described in the specification.

  该发明涉及一种在合成具有含有4-甲基取代噻吩核的GARFT抑制剂的关键中间体的过程，其中所述关键中间体具有以下结构式（I）： 其中R1和R2各自独立地是一个与所附CO2形成易水解酯基的基团；从具有以下结构式（VI）的化合物中： 其中R1如上所述，Pg1是氨基保护基团，Pg2是醚基保护基团；其中所述过程如规范中描述。